Skip to main
TRVI

TRVI Stock Forecast & Price Target

TRVI Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trevi Therapeutics is well-positioned for future success and revenue growth with their investigational therapy Haduvio, as seen through their recent positive clinical trial results and planned Phase 3 trials for IPF-related chronic cough and RCC. The company has also taken measures to strengthen their financial position, including hosting an Analyst Day and successfully completing a $150 million stock offering. While there are still risks involved in the clinical development and potential commercialization of Haduvio, Trevi Therapeutics shows promising potential as a leader in the treatment of chronic cough.

Bears say

Trevi Therapeutics is taking a multi-indication approach with the investigational therapy Haduvio, but a lack of approved therapies in chronic cough populations and potential financial risks from partnerships and acquisitions may limit its success. With upcoming catalysts in the form of trials and an investor day, the stock could see some short-term gains, but a negative outlook remains due to the lack of approved therapies and potential risks.

TRVI has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trevi Therapeutics Inc (TRVI) Forecast

Analysts have given TRVI a Strong Buy based on their latest research and market trends.

According to 11 analysts, TRVI has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trevi Therapeutics Inc (TRVI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.